Katharina Schwarzkopf, Joerg Bojunga, Sabrina Rüschenbaum, Yolanda Martinez, Marcus M. Mücke, Florian Seeger, Fabian Schoelzel, Stefan Zeuzem, Mireen Friedrich‐Rust, Christian M. Lange – 5 October 2018 – Platelets participate in the development of liver fibrosis in animal models, but little is known about the benefit of antiplatelet agents in preventing liver fibrosis in humans. We therefore explored the relationship between the use of antiplatelet agents and liver fibrosis in a prospective cohort study of patients at high risk of liver fibrosis and cardiovascular events.

Daniel H. Leung, Stefan Wirth, Betty B. Yao, Rolando M. Viani, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, Steven J. Lobritto, Michael R. Narkewicz, Etienne Sokal, Clàudia Fortuny, Evelyn K. Hsu, Antonio Del Valle‐Segarra, Jiuhong Zha, Lois Larsen, Li Liu, Diana L. Shuster, Daniel E. Cohen, Philip Rosenthal – 5 October 2018 – In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR).

Haesuk Park, Wei Wang, Linda Henry, David R. Nelson – 5 October 2018 – Approved treatment for hepatitis C virus (HCV) with all‐oral direct‐acting antivirals (DAA) therapy is now entering into its fourth year; however, little has been reported on the real‐world clinical (decompensated cirrhosis [DCC] and hepatocellular carcinoma [HCC]) and economic outcomes. A retrospective cohort analysis of the Truven Health MarketScan Database (2012‐2016) was conducted.

5 October 2018

William S. Blaner – 4 October 2018

Hao Zhang, Yanqiu Zhang, Xiaoyun Zhu, Chen Chen, Chao Zhang, Yuanzheng Xia, Yucheng Zhao, Ourania Andrisani, Lingyi Kong – 3 October 2018 – In hepatocellular carcinoma (HCC), dysregulated expression of DDX5 (DEAD box protein 5) and impaired autophagy have been reported separately. However, the relationship between them has not been explored. Here we present evidence to show that, by interacting with autophagic receptor p62, DDX5 promotes autophagy and suppresses tumorigenesis.

Abhinav Anand, Shalimar – 3 October 2018

Tianpeng Zhang, Jiangyan Duan, Lei Zhang, Zhuoyu Li, Clifford J. Steer, Guiqin Yan, Guisheng Song – 3 October 2018 – Nonalcoholic fatty liver disease (NAFLD) is a major risk factor of many end‐stage liver diseases. Alterations in microRNA expression have been reported in patients with NAFLD. However, the transcriptional mechanism(s) of dysregulated microRNAs under the state of NAFLD is poorly described, and microRNAs that regulate the pathogenesis of NAFLD synergistically with their regulators remain unknown.

Jin Ge, Evelyn K. Hsu, John Bucuvalas, Jennifer C. Lai – 3 October 2018 – Each year, approximately 60 children, representing 12% of waitlist candidates, die awaiting liver transplantation. The current allocation algorithm for pediatric donor livers prioritizes local/regional adults over national children. We attempted to better understand the impact of the present algorithm on pediatric candidates. We analyzed pediatric donor liver offers from 2010 to 2014. Donors and recipients were classified based on age.

Shane A. Wells, Timothy J. Ziemlewicz, Meghan G. Lubner – 2 October 2018